CDEFGHIJKLMNO
2
0
Best Practices
- Expand the formula bar so that you don't miss the additional info found in some of the cells. Reference the image to the right for more help.
- Use filters to explore and organize the information for your own use. When accessing through this view-only link, filters are temporary to that search/find.
- This document is also available for download under the File tab.
- To find the latest additions or updates to the tracker, command+F or control+F and search for an asterisk. All cells with new information have an added at the end.
Last Update: May 21, 2020 | 12:37 pm ET
© 2020 Milken Institute00
2020
3
Treatment vs. VaccineProduct CategoryProduct DescriptionStage of Development Anticipated Next StepsClinical Trials for COVID-19Developer / Researcher FunderPublished ResultsClinical Trials for Other Diseases
(T only)

Related Use /
Platform
(V Only)		FDA-Approved IndicationsSourcesDate Last Updated
4
TreatmentAntibodiesPolyclonal hyperimmune globulin (H-IG), unbrandedPre-clinicalPhase 1 trials start in summer 2020. To patients between December 2020 and December 2021CoVIg-19 Plasma Alliance (Takeda, CSL Behring, Biotest AG, Bio Products Laboratory, LFB, and Octapharma, ADMA Biologics, BioPharma Plasma, GC Pharma, Sanquin)/ National Institute of Allergy and Infectious Disease (NIAID)/ Microsoft (CoVIg-19 PlasmaBot)N/ASources5/10/2020
5
TreatmentAntibodiesAntibodies from mice, REGN3048-3051, against the spike proteinPre-clinicalStart Phase 1 June 2020RegeneronBiomedical Advanced Research and Development Authority (BARDA)N/ASourcesPrior to 4/20/2020
6
TreatmentAntibodiesCT-P59; Antibodies from recovered COVID-19 patients
Pre-clinicalStart Phase 1 in July 2020CelltrionThe Korea Health Industry Development InstituteN/ASources5/14/2020
7
TreatmentAntibodiesSuper-antibody or antibody cocktail to target potential mutations of SARS-CoV-2Pre-clinicalCelltrionN/ASourcesPrior to 4/20/2020
8
TreatmentAntibodiesCOVI-SHIELD antibody cocktail that binds to three different epitopesPre-clinicalStart Phase 2 trial 3Q 2020
Sorrento Therapeutics/ Mount Sinai Health System
N/ASources5/20/2020
9
TreatmentAntibodiesAntibodies from recovered COVID-19 patientsPre-clinicalKamada/ Kedrion BiopharmaN/ASources5/4/2020
10
TreatmentAntibodiesVIR-7831 and VIR-7832, antibodies from recovered SARS patientsPre-clinicalStart Phase 2 ~ July-September 2020Vir Biotechnology/GSK/ Samsung/WuXi Biologics/BiogenN/ASources5/20/2020
11
TreatmentAntibodiesAntibodies from recovered COVID-19 patientsPre-clinicalStart Phase 1 in late July 2020Eli Lilly/Ab-Cellera (NIH Vaccines Research Center)Defense Advanced Research Projects Agency/ Government of Canada (ISED Strategic Innovation Fund)N/ASources5/5/2020
12
TreatmentAntibodiesCOVID-19 Immunoglobulin, plasma derived
Pre-clinicalCSL Behring Australia
N/ASources5/10/2020
13
TreatmentAntibodiesAvastin (bevacizumab), vascular endothelial growth factor inhibitorClinicalPhase 2/3 studies recruiting April 2020NCT04275414

NCT04305106

NCT04344782

Numerous trials with Chinese research sponsors; RocheFDA-approved since 2004, approved to treat certain types of cancerSources4/27/2020
14
TreatmentAntibodiesPD-1 blocking antibody; ThymosinClinicalPhase 2 study not yet recruiting
NCT04268537

ChiCTR2000030028 		Numerous trials with Chinese research sponsorsUnknownSources4/27/2020
15
TreatmentAntibodiesOpdivo (nivolumab), PD-1 blocking antibodyClinicalPhase 2 study not yet recruiting
NCT04356508

NCT04333914 		University of Hong Kong (BMS)FDA-approved since 2014, approved to treat melanoma and squamous non-small cell lung cancerSources4/27/2020
16
TreatmentAntibodiesleronlimab (PRO 140), a CCR5 antagonistClinical / Compassionate UsePhase 2 trial started in April 2020; Phase 2b/3 trial starts April 2020NCT04343651

NCT04347239		CytoDynCytoDynTreatment of HIV/AIDS, Graft versus Host Disease, Non-Alcoholic Steatohepatitis, and numerous cancersN/ASourcesPrior to 4/20/2020
17
TreatmentAntibodiesAiRuiKa (camrelizumab), anti-programmed cell death protein (PD-1) antibodyClinicalNo trial updates since February 2020
ChiCTR2000029806Wuhan Jinyintan HospitalTreatment of certain cancersN/ASources4/27/2020
18
TreatmentAntibodiesKevzara (sarilumab), interleukin-6 receptor antagonistClinicalStarted phase 2/3 in March 2020; preliminary Phase 2 results released April 27, 2020, trial continuing for only critical patients, Phase 3 (US) results expected June 2020, Phase 3 (ex-US) results expected 3Q 2020NCT04315298

NCT04321993

NCT04341870

NCT04324073

NCT04327388

NCT04322773

NCT04345289

NCT02735707

NCT04357808

NCT04357860

NCT04359901

Sanofi/Regeneron; Feinstein Institutes; REMAP-CAP global trialBiomedical Advanced Research and Development Authority (BARDA)medRxiv (https://doi.org/10.1101/2020.04.23.20076612)

Regeneron (https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive)

ChinaXiv (http://www.chinaxiv.org/abs/202003.00026)

medRxiv (https://doi.org/10.1101/2020.05.14.20094144)		FDA-approved since 2017, approved to treat rheumatoid
arthritis		Sources5/20/2020
19
TreatmentAntibodiesActemra (tocilizumab), interleukin-6 receptor antagonistClinicalRoche studies could be completed May or June 2020; Phase 2 open label study in Italy active (April 2020), Phase 3 studies recruiting April 2020, some results from open label study in France released April 2020NCT04317092

NCT04320615

NCT04310228

ChiCTR2000030894

NCT04306705

ChiCTR2000030442

ChiCTR2000029765

NCT04322773

NCT04345445

NCT04331795

NCT04332094

NCT04346355

NCT04359667

NCT04332913

NCT04335071

NCT04356937

NCT04361032

NCT04315480

NCT04339712

NCT04333914

NCT04361552

NCT04330638

NCT04331808

NCT02735707

NCT04349410

NCT04363736

NCT04372186

NCT04363853		Numerous trials with global research sponsors; Roche; REMAP-CAP
Biomedical Advanced Research and Development Authority (BARDA)ChinaXiv (http://www.chinaxiv.org/abs/202003.00026)

medRxiv (https://doi.org/10.1101/2020.04.20.20061861)

medRxiv (https://doi.org/10.1101/2020.04.23.20076612)

Assistance Publique Hopitaux De Paris (https://www.aphp.fr/contenu/le-tocilizumab-ameliore-significativement-le-pronostic-des-patients-avec-pneumonie-covid)

PNAS (https://www.pnas.org/content/early/2020/04/27/2005615117#T1)

medRxiv (https://doi.org/10.1101/2020.05.01.20078360)

medRxiv (https://doi.org/10.1101/2020.05.07.20094599)

medRxiv (https://doi.org/10.1101/2020.05.14.20099234)

medRxiv (https://doi.org/10.1101/2020.05.13.20100404)

medRxiv (https://doi.org/10.1101/2020.05.13.20100081)
FDA-approved since 2010, approved to treat various type of arthritis, including rheumatoid arthritis, and cytokine release syndromeSources5/21/2020
20
TreatmentAntibodiesGimsilumab, anti-granulocyte-macrophage colony stimulating factor monoclonalClinicalPhase 2 study started in April 2020NCT04351243Roivant SciencesN/ASources5/14/2020
21
TreatmentAntibodiesTJM2 (TJ003234), anti-granulocyte-macrophage colony stimulating factor antibodyClinicalPhase 1/2 recruiting April 2020
NCT04341116I-Mab BiopharmaN/ASources4/27/2020
22
TreatmentAntibodieslenzilumab, anti-granulocyte-macrophage colony stimulating factor antibodyClinical / Compassionate UsePhase 3 not yet recruiting April 2020
NCT04351152Humanigen Inc.Prevent cytokine storm with CAR-T cancer therapy; prevention/treatment of acute graft versus host disease; chronic myelomonocytic leukemia; eosinophilic asthmaN/ASources4/27/2020
23
TreatmentAntibodiesSylvant (siltuximab), interleukin-6 targeted monoclonalClinical / Compassionate UseCompassionate use data shared April 2020; Phase 3 recruiting April 2020
NCT04322188

NCT04330638

NCT04329650		EUSA Pharma/The Papa Giovanni XXII Hospital; University Hospital, Ghent; Fundacion Clinic per a la Recerca BiomédicaEUSA Pharma (https://www.eusapharma.com/news/interim-analysis-data-for-siltuximab-treated-covid-19-patients-from-the-sisco-study/)

medRxiv (https://doi.org/10.1101/2020.04.01.20048561)

medRxiv (https://doi.org/10.1101/2020.04.23.20076612)		FDA-approved since 2014, approved to treat multicentric Castleman diseaseSources4/28/2020
24
TreatmentAntibodiesSoliris (eculizumab), complement inhibitorClinical/ Expanded accessPhase 2 recruiting May 2020NCT04288713

NCT04346797

NCT04355494 		Assistance Publique - Hopitaux de Paris (Phase 2); Alexion (Expanded Access)FDA-approved since 2007, approved to treat Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, and Neuromyelitis Optica Spectrum DisorderSources5/5/2020
25
TreatmentAntibodiesIlaris (canakinumab), interleukin-1beta blockerClinicalNovartis Phase 3 to start and trial top-line results expected late summer 2020NCT04348448

NCT04362813

NCT04365153		Novartis; other research sponsors
FDA-approved since 2009, approved to treat periodic fever syndromes and systemic juvenile idiopathic arthritisSources4/30/2020
26
TreatmentAntibodiesGamifant (emapalumab), anti-interferon gamma antibodyClinicalPhase 2/3 recruiting April 2020
NCT04324021Swedish Orphan BiovitrumFDA-approved since 2018, approved to treat primary hemophagocytic lymphohistiocytosisSources4/27/2020
27
TreatmentAntibodiesmeplazumab, anti-CD147 antibodyClinicalPhase 1/2 recruiting April 2020
NCT04275245Tang-Du HospitalmedRxiv (https://doi.org/10.1101/2020.03.21.20040691)N/ASources4/27/2020
28
TreatmentAntibodiesLY3127804, anti-Angiopoietin 2 (Ang2) antibodyClinicalPhase 2 to start in April 2020Eli LillyN/ASourcesPrior to 4/20/2020
29
TreatmentAntibodiesUltomiris (ravulizumab-cwvz), complement inhibitorClinicalPhase 3 to start in May 2020NCT04369469Alexion PharmaceuticalsFDA-approved since 2018, aprpoved to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndromeSources5/5/2020
30
TreatmentAntibodiesIFX-1, anti-C5a antibodyClinicalPhase 2/3 recruiting in April 2020
NCT04333420InflaRx N.V.To treat various inflammatory conditions including hidradenitis suppurativa, ANCA-associated vasculitis, and pyoderma gangraenosumN/ASources4/27/2020
31
TreatmentAntibodiesotilimab, anti-granulocyte macrophase colony-stimulating factor (GM-CSF) antibody
ClinicalPhase 2 to start end of May 2020
NCT04376684GSKTo treat rheumatoid arthritis
N/ASources5/8/2020
32
TreatmentAntibodiesMonoclonal antibody cocktailPre-clinicalImmunoPrecise AntibodiesN/ASources4/23/2020
33
TreatmentAntibodiesAntibodyPre-clinicalHarbour BioMed/ Erasmus MC/ Utrecht University/ Mount Sinai Health System
N/ASources5/10/2020
34
TreatmentAntibodiesAntibodies targeting the S protein from convalescent serum, humanized mice, and phage displayPre-clinicalPhase 1 trials begin in summer 2020AstraZeneca/ US Army Medical Research Institute of Infectious Diseases (USAMRIID)/ University of Maryland School of MedicineN/ASourcesPrior to 4/20/2020
35
TreatmentAntibodiesAntibodyPre-clinicalCentivax (Distributed Bio)N/ASources5/21/2020
36
TreatmentAntibodiesAntibodiesPre-clinicalChelsea and Westminster Hospital, Imperial College LondonUK GovernmentN/ASources5/10/2020
37
TreatmentAntibodiesAntibodyPre-clinicalPhase 1 trial begins in summer 2020Vanderbilt Vaccine Center/ AstraZeneca/ IDBiologics
Defense Advanced Research Projects Agency/ Dolly PartonN/ASources5/10/2020
38
TreatmentAntibodiesAntibodiesPre-clinicalMedicago/ Laval University's Infectious Disease Research CentreCanadian Institutes for Health Research (CIHR)N/ASourcesPrior to 4/20/2020
39
TreatmentAntibodiesAntibodiesPre-clinicalFairJourney Biologics/ IontasN/ASources4/21/2020
40
TreatmentAntibodiesAntibodiesPre-clinicalPrellis BiologicsN/ASources5/21/2020
41
TreatmentAntibodiesAntibodies (OmniChicken platform)Pre-clinicalLigand PharmaceuticalsN/ASources4/23/2020
42
TreatmentAntibodiesAntibodies (OmniRat platform)Pre-clinicalLigand PharmaceuticalsN/ASources4/23/2020
43
TreatmentAntibodiesMonocloncal antibodies, TLR4 antagonistPre-clinicalEdesa Biotech/ Light Chain Bioscience (NovImmune)N/ASources4/23/2020
44
TreatmentAntibodiesMonocloncal antibodies, CXC10 antagonistPre-clinicalEdesa Biotech/ Light Chain Bioscience (NovImmune)N/ASources4/23/2020
45
TreatmentAntibodiesPolyclonal hyperimmune globulin (H-IG)Pre-clinicalPhase 2 trials begin ~ August 2020Emergent BioSolutions/ National Institute of Allergy and Infectious Diseases (NIAID)Biomedical Advanced Research and Development Authority (BARDA)Same human hyperimmune platform as FDA-approved anthrax treatment (Anthrasil) and smallpox vaccine complications (VIGIV) were developedN/ASourcesPrior to 4/20/2020
46
TreatmentAntibodiesHorse plasma product (COVID-EIG)Pre-clinicalPhase 2 trials begin ~ August 2020Emergent BioSolutionsSame equine hyperimmune platform as FDA-approved botulism anti-toxin (BAT) is producedN/ASourcesPrior to 4/20/2020
47
TreatmentAntibodiesConvalescent plasma (blood plasma from recovered patients)Clinical / Expanded AccessPhase 2 and Phase 3 trials not yet recruiting as of April 2020
Many expanded access, observational, patient registry, plasma collection, prevention, and other studies listed in clincialtrials.gov, including:

NCT04321421

NCT04292340

NCT04316728

NCT04338360

NCT04345289

NCT04349410

NCT04346589

NCT04333251

NCT04361253

NCT04323800

NCT04359810

NCT04362176

NCT04354831

NCT04360486

Multiple global research sponsors, including New York State Department of Health, Johns Hopkins University, the Feinstein InstitutesBloomberg Philantropies and the State of Maryland (to Johns Hopkins University)/ Biomedical Advanced Research and Development Authority (BARDA) (to Mayo Clinic)medRxiv (https://doi.org/10.1101/2020.03.16.20036145)

JAMA (https://jamanetwork.com/journals/jama/fullarticle/2763983)

medRxiv (https://doi.org/10.1101/2020.04.07.20056440)

JAMA Network (https://jamanetwork.com/journals/jama/fullarticle/2763982)

medRxiv (https://doi.org/10.1101/2020.05.08.20095471)

medRxiv (https://doi.org/10.1101/2020.05.12.20099879)		N/ASources5/20/2020
48
TreatmentAntibodiesAntibodies from recovered COVID-19 patientsPre-clinicalPhase 1 trial begins Q3 2020Tsinghua University / Third People's Hospital of Shenzhen / Brii BiosciencesN/ASourcesPrior to 4/20/2020
49
TreatmentAntibodiesPolyclonal hyperimmune globulin (H-IG)Pre-clinicalGrifolsBiomedical Advanced Research and Development Authority (BARDA)N/ASourcesPrior to 4/20/2020
50
TreatmentAntibodiesAntibodies from recovered COVID-19 patientsPre-clinicalGrifolsBiomedical Advanced Research and Development Authority (BARDA)N/ASourcesPrior to 4/20/2020
51
TreatmentAntibodiesAntibodies from recovered COVID-19 patientsPre-clinicalAmgen / Adaptive BiotechnologiesN/ASourcesPrior to 4/20/2020
52
TreatmentAntibodiesAntibodies from recovered COVID-19 patientsPre-clinicalInnovent BiologicsN/ASourcesPrior to 4/20/2020
53
TreatmentAntibodiesAntibodies from recovered COVID-19 patientsPre-clinicalXbiotech / BioBridge GlobalN/ASourcesPrior to 4/20/2020
54
TreatmentAntibodiesAntibodies from recovered COVID-19 patientsPre-clinicalCosta Rican Social Security Fund (CCSS)/ The University of Costa Rica (UCR)/ Clodomiro Picado InstituteN/ASourcesPrior to 4/20/2020
55
TreatmentAntibodiesNovel IgM and IgA antibodies
Pre-clinicalAtreca/ BeiGene/ IGM Biosciences
N/ASources5/4/2020
56
TreatmentAntibodiesSAB-185, Polyclonal hyperimmune globulin (H-IG)Pre-clinicalPhase 1 starts early summer 2020CSL Behring/ SAb BiotherapeuticsBiomedical Advanced Research and Development Authority (BARDA)/ US Department of DefenseN/ASources4/30/2020
57
TreatmentAntibodiesNon-viral gene therapy to produce monoclonal antibodiesPre-clinicalGeneration Bio / Vir BiotechnologyN/ASourcesPrior to 4/20/2020
58
TreatmentAntibodiesrCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin), polyclonal antibodiesPre-clinicalGigaGenN//ASourcesPrior to 4/20/2020
59
TreatmentAntibodiesIC14, recombinant chimeric anti-CD14 monoclonal antibodyExpanded accessNCT04346277Implicit BioscienceAcute Respiratory Distress SyndromeN/ASourcesPrior to 4/20/2020
60
TreatmentAntibodiesMEDI3506, monoclonal antibody targeting interleukin 33ClinicalACCORD Phase 2 trial to start May 2020AstraZeneca; ACCORD trial UK Government (ACCORD study)Chronic Obstructive Pulmonary DiesaseN/ASources5/10/2020
61
TreatmentAntibodiesOctagam; intravenous Immunoglobulin (IVIG)ClinicalPhase 3 trial to start May 2020
NCT04261426

NCT04264858

NCT04350580		Multiple global research sponsors; Octapharma USA/ Sharp Memorial HospitalOpen Forum Infectious Diseases (https://academic.oup.com/ofid/article/7/3/ofaa102/5810740)FDA-approved since 2014, approved to treat chronic immune thrombocytopenic purpura (ITP)Sources5/21/2020
62
TreatmentAntibodiesPurified ovine immunoglobulin from immunized sheepPre-clinicalPublic Health England (Stuart Dowall)UK GovernmentN/ASources4/23/2020
63
TreatmentAntibodiesAntibodiesPre-clinicalAblexis/ AlivaMab Discovery Services/ Berkeley Lights Collaborate
N/A
Sources4/28/2020
64
TreatmentAntibodiesJS016 antibody candidate
Pre-clinicalPhase 1 to start 2Q 2020Junshi Biosciences/ Eli LillyN/ASources5/5/2020
65
TreatmentAntibodiesLinked nanobody antibodyPre-clinicalUniversity of Texas at Austin/ US National Institutes of Health/ Ghent UniversityN/ASources5/1/2020
66
TreatmentAntibodiesSingle domain antibodies (sdAbs), engineered monoclonal antibody derived from camelidsPre-clinicalAbcoreN/ASources5/21/2020
67
TreatmentAntiviralsFavilavir/Favipiravir/T-705/Avigan, licensed in Japan to treat influenzaClinicalPhase 3 trial in Japan started in March 2020; Phase 2 trial in US started April 2020; Phase 3 trial in India started May 2020 with results expected by July/August 2020 (Glenmark)NCT04303299

NCT04310228

ChiCTR2000029548

ChiCTR2000029496

ChiCTR2000029544

ChiCTR2000030254

NCT04336904

NCT04333589

NCT04345419		Fujifilm Toyama Chemical/Zhejiang Hisun Pharmaceuticals/numerous trials with global research sponsors/ Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School/ Glenmark PharmaceuticalsmedRxiv (https://doi.org/10.1101/2020.03.17.20037432)

medRxiv (https://doi.org/10.1101/2020.04.21.20066761)

Kyodo News (https://english.kyodonews.net/news/2020/05/fce701d4d88d-antiflu-avigan-not-showing-apparent-efficacy-in-coronavirus-treatment.html)		N/ASources5/21/2020
68
TreatmentAntiviralsKaletra/Aluvia (lopinavir/ritonavir), HIV-1 protease inhibitorClinicalRECOVERY trial results expected by June 2020NCT04303299

NCT04255017

ChiCTR2000029548

ChiCTR2000029539

EudraCT 2020-000936-23

NCT04307693

NCT04315948

NCT04252885

NCT04276688

NCT02735707

NCT04321993

2020-001113-21

NCT04286503

NCT04328012

NCT04346147		Global hospital testing (AbbVie); World Health Organization SOLIDARITY trial (studying lopinavir/ ritonavir with and without interferon beta); University of Oxford RECOVERY trial; REMAP-CAP global trialUK Government (University of Oxford RECOVERY trial)NEJM (https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true)

medRxiv (https://doi.org/10.1101/2020.03.19.20038984)

Chinese Journal of Infectious Diseases (http://rs.yiigle.com/yufabiao/1182592.htm)

medRxiv (https://doi.org/10.1101/2020.03.28.20045955)

medRxiv (https://doi.org/10.1101/2020.04.08.20057539)

medRxiv (https://doi.org/10.1101/2020.04.21.20066761)

medRxiv (https://doi.org/10.1101/2020.04.25.20079079)

medRxiv (https://doi.org/10.1101/2020.04.24.20077735)

The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext)

medRxiv (https://doi.org/10.1101/2020.05.13.20094193)		FDA-approved since 2000, approved to treat HIV-1 infectionSources5/20/2020
69
TreatmentAntiviralsremdesivir, nucleotide analogClinical / Expanded Access / FDA issued an Emergency Use Authorization on May 1, 2020Gilead Phase 3 trial topline results released April 2020 (severe disease) and expected May 2020 (moderate disease); NIAID trial preliminary data released April 2020, full results expected in May 2020NCT04257656

NCT04252664

NCT04292730

NCT04292899

NCT04280705

EudraCT 2020-000936-23

NCT04315948

NCT04302766

NCT04323761

NCT04349410		Gilead; World Health Organization SOLIDARITY trial; National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial; Feinstein InstitutesNEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2007016)

NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2001191)

Stat News (https://www.statnews.com/2020/04/16/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment/)

Reuters (https://www.reuters.com/article/us-health-coronavirus-gilead-sciences/gilead-disputes-report-that-coronavirus-drug-trial-flopped-idUSKCN225326)

Stat (https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/)

medRxiv (https://doi.org/10.1101/2020.04.21.20066761)

Gilead (https://www.businesswire.com/news/home/20200429005424/en/Gilead-Announces-Results-Phase-3-Trial-Investigational)

NIAID (https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19?utm_campaign=+42538088&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=)

Lancet (https://doi.org/10.1016/S0140-6736(20)31022-9)

medRxiv (https://doi.org/10.1101/2020.05.02.20088559)		Treatment of EbolaN/ASources5/20/2020
70
TreatmentAntiviralsPrezcobix (darunavir, HIV-1 protease inhibitor/cobicistat, CYP3A inhibitor)ClinicalPhase 3 trials recruiting May 2020
ChiCTR2000029541

NCT04252274

NCT04303299

NCT04304053		Multiple global research sponsors
FDA-approved since 2015, approved to treat HIV-1 infectionSources5/20/2020
71
TreatmentAntiviralsgalidesivirClinicalPhase 1b recruiting May 2020
NCT03891420BioCryst PharmaceuticalsNational Institute of Allergy and Infectious Diseases (NIAID)Treatment of yellow feverN/ASources5/7/2020
72
TreatmentAntiviralsGanovo (danoprevir), hepatitis C virus NS3 protease inhibitor; ritonavir; interferon, approved in China to treat Hepatitis CClinicalSmall open label trial completed and results released in March 2020; Larger open label trial recruiting May 2020NCT04291729

NCT04345276		Ascletis/Chinese research sponsorsmedRxiv (https://doi.org/10.1101/2020.03.22.20034041)Treatment of Hepatitis C
N/ASources5/7/2020
73
TreatmentAntiviralsASC09, HIV protease inhibitorClinicalPhase 3 trial recruiting May 2020
NCT04261907

NCT04261270		Ascletis/Chinese research sponsors
Treatment of HIV/AIDSN/ASources5/7/2020
74
TreatmentAntiviralsTruvada (emtricitabine and tenofovir, both HIV-1 nucleoside analog reverse transcriptase inhibitors)ClinicalPhase 3 trial recruiting May 2020
ChiCTR2000029468

NCT04334928		Plan Nacional sobre el Sida
FDA-approved since 2004, approved to treat and prevent HIV-1 infectionSources5/7/2020
75
TreatmentAntiviralsArbidol (umifenovir), licensed in Russia and China for treatment of respiratory viral infectionsClinicalPhase 4 trials recruiting May 2020NCT04252885

NCT04350684

NCT04286503

NCT04260594

NCT04273763		Multiple global research sponsors
medRxiv (https://doi.org/10.1101/2020.03.19.20038984)

Chinese Journal of Infectious Diseases (http://rs.yiigle.com/yufabiao/1182592.htm)

medRxiv (https://doi.org/10.1101/2020.03.17.20037432)

medRxiv (https://doi.org/10.1101/2020.03.28.20045955)

medRxiv (https://doi.org/10.1101/2020.04.08.20057539)

medRxiv (https://doi.org/10.1101/2020.04.06.20042580)

medRxiv (https://doi.org/10.1101/2020.04.11.20056523)

medRxiv (https://doi.org/10.1101/2020.04.25.20079079)		N/ASources5/7/2020
76
TreatmentAntiviralsVicromax, broad spectrum antiviralPre-clinicalViralClear PharmaceuticalsSourcesPrior to 4/20/2020
77
TreatmentAntiviralsISR-50Pre-clinicalISR Immune System RegulationN/ASourcesPrior to 4/20/2020
78
TreatmentAntiviralsTamiflu (oseltamivir), neuraminidase inhibitorClinicalREMAP-CAP trial recruiting May 2020
NCT04303299

NCT04255017

NCT04261270

NCT02735707

NCT04338698

NCT04371601		Roche; REMAP-CAP global trialmedRxiv (https://doi.org/10.1101/2020.03.28.20045955)

medRxiv (https://doi.org/10.1101/2020.04.11.20056523)		FDA-approved since 1999, approved to treat and prevent influenzaSources5/7/2020
79
TreatmentAntiviralsantiviral Fc conjugatesPre-clinicalCidara TherapeuticsN/ASourcesPrior to 4/20/2020
80
TreatmentAntiviralsAntiviral compoundsPre-clinicalCocrystal PharmaN/ASourcesPrior to 4/20/2020
81
TreatmentAntiviralsEIDD-2801, oral ribonucleoside analogClinicalPhase 1 started April 2020Ridgeback Biotherapeutics / Drug Innovation Ventures at Emory (DRIVE)N/ASourcesPrior to 4/20/2020
82
TreatmentAntiviralsVirazole (ribavirin for inhalation solution)Clinical / Compassionate UsePhase 1 recruiting May 2020NCT04356677Bausch HealthFDA-approved since 1985, approved to treat lower respiratory tract infections due to RSVSources5/7/2020
83
TreatmentAntiviralsAntiviral drug combinationsPre-clinicalSCORE consortium (universities of Aix-Marseille, Leuven, Utrecht, Bern, and Lubeck), the Helmholtz Centre for Infection Research, and Janssen Pharmaceutica NVEU Commission (Horizon 2020 Program)UnknownSourcesPrior to 4/20/2020
84
TreatmentAntiviralsLevovir (clevudine)ClinicalPhase 2 trial not yet recruiting
NCT04347915Bukwang PharmSources5/7/2020
85
TreatmentAntiviralsAB001Pre-clinicalPhase 1 to start in 2020Agastiya BiotechN/ASources4/24/2020
86
TreatmentAntiviralsBTL-tml
ClinicalHas been used in 36 patients anecdotally
Beech Tree Labs
Treatment of herpes virus infections
N/ASources5/5/2020
87
TreatmentAntiviralsDAS181, recombinant sialidase (nebulized)
Compassionate Use/ ClinicalCompassionate use finding released in May 2020; Phase 2/3 started enrolling in May 2020
NCT03808922

NCT04354389

NCT04298060

NCT04324489		Ansun Biopharma/ Renmin Hospital of Wuhan University
PR Newswire (https://www.prnewswire.com/news-releases/ansun-biopharma-announces-positive-results-from-investigator-initiated-trial-of-novel-covid-19-treatment-301033871.html)Treatment of lower respiratory tract parainfluenza virus infections and severe influenza infectionsN/ASources5/5/2020
88
TreatmentAntiviralsemetine hydrochloride
ClinicalPhase 2/3 to start in Q3 2020
Acer Therapeutics/ US National Center for Advancing Translational Sciences (NCATS)To treat viral hepatitis and varicella-virus
N/ASources5/13/2020
89
TreatmentAntiviralsAT-527, oral purine nucleotide prodrugClinicalPhase 2 trial to start May 2020NCT04396106Atea PharmaceuticalsTreatment of Hepatitis C infectionsN/ASources5/21/2020
90
TreatmentCell-based therapiesPLX cell product, placenta-based cell therapyClinical/ Compassionate Use
Results from compassionate use released in April 2020
Pluristem Therapeutics/BIH Center for Regenerative Therapy/Berlin Center for Advanced TherapiesPluristem Therapeutics (https://www.pluristem.com/wp-content/uploads/2020/04/PSTI-PR-Follow-up-on-Covid-19-treatments-FINAL-FOR-RELEASE.pdf)Various conditions
N/ASources5/8/2020
91
TreatmentCell-based therapiesMesenchymal stem cellsClinicalPhase 1 trials ongoing May 2020; Phase 1/2 trials recruiting May 2020; Phase 2/3 trial recruiting May 202030 trials listed in clinicaltrials.gov

ChiCTR2000029990

NCT04315987

NCT04302519

NCT04288102

NCT04313322

NCT04273646

NCT04371601

NCT04315987

NCT04252118

NCT04336254

NCT04339660

NCT04371601

NCT04366063		Numerous trials with global research sponsorsAging and Disease (http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml)

ChinaXiv (http://chinaxiv.org/abs/202002.00084)		N/ASources5/8/2020
92
TreatmentCell-based therapiesAutologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs)Expanded accessCelltexCelltex (https://celltexbank.com/transplantation-of-ace2-mesenchymal-stem-cells-improves-the-outcome-of-patients-with-covid-19-pneumonia/)

Celltex (https://celltexbank.com/chinaxiv-reports-clinical-remission-of-a-critically-ill-covid-19-patient-treated-by-human-umbilical-cord-mesenchymal-stem-cells/)		Injuries, Pain, and Autoimmune, Vascular and Other Disease, including Inflammatory lung conditions, pneumonia, and chronic obstructive pulmonary disease (COPD)N/ASources5/13/2020
93
TreatmentCell-based therapiesRyoncil (remestemcel-L), allogenic mesenchymal stem cellsClinical/ Compassionate Use/ Expanded AccessCompassionate use data shared April 2020; Phase 3 trial recruiting May 2020
NCT04366830

NCT04371393		Mesoblast/ Cardiothoracic Surgical Trials NetworkMesoblast (http://investorsmedia.mesoblast.com/static-files/337e723a-340d-493e-a4a1-0971d2c71460)Graft versus host disease and other rare diseases, chronic obstructive pulmonary diseaseN/ASources5/7/2020
94
TreatmentCell-based therapiesMultiStem, bone marrow stem cellsClinicalPhase 2/3 trial recruiting May 2020
NCT04367077Athersys / The University of Texas Health Science Center at HoustonMedical Technology Enterprise Consortium (MTEC)Acute Respiratory Distress Syndrome; StrokeSources5/10/2020
95
TreatmentCell-based therapiesAllogeneic T-cell therapiesPre-clinicalAlloVir/Baylor College of MedicineN/ASourcesPrior to 4/20/2020
96
TreatmentCell-based therapiesNatural killer cell-based therapyPre-clinicalBegin Phase 1 by end of 2020GC LabCell / KLEO PharmaceuticalsN/ASourcesPrior to 4/20/2020
97
TreatmentCell-based therapiesCYNK-001, allogeneic, natural killer cell therapyClinicalPhase 1/2 study not yet recruiting May 2020
NCT04365101Celularity/ Lung Biotechnology PBCVarious hematologic cancers and solid tumorsN/ASources5/7/2020
98
TreatmentCell-based therapiesCAP-1002, allogenic cardiosphere-derived cellsExpanded accessExpanded access trial ongoing May 2020
NCT04338347Capricor Inc.Duchenne muscular dystrophyN/ASources5/7/2020
99
TreatmentCell-based therapieshaNK, natural killer cellsClinicalImmunityBio / NantKwestN/ASources5/21/2020
100
TreatmentCell-based therapiesBone marrow-derived allogenic mesenchymal stem cells (BM-Allo-MSC)Pre-clinicalPhase 1b trial to start in Q2 2020ImmunityBio/ NantKwest/ Be The Match BioTherapiesN/ASources5/21/2020
101
TreatmentCell-based therapiesAllogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)ClinicalPhase 2 started in April 2020NCT04348435

NCT04349631

NCT04362189		Hope BiosciencesHope Biosciences Stem Cell Research FoundationRheumatoid arthritisN/ASources4/24/2020